Literature DB >> 28432174

Postintervention acute opsoclonus myoclonus syndrome.

Annelise Aquilina1, Nicola Dingli2, Josanne Aquilina3.   

Abstract

Opsoclonus myoclonus syndrome (OMS) is a rare, neurological condition affecting 1 in 10 000 000 people annually. Opsoclonus, defined as involuntary rapid, multivectorial oscillations of the eyes, together with ataxia and myoclonus are usually present. OMS may be paraneoplastic: often associated with occult neuroblastoma in childhood and with breast carcinoma or small cell lung carcinoma in adults. Other aetiologies include viral or toxic agents. The pathogenesis is thought to be immune mediated. A 37-year-old woman with previous inflammatory cranial mononeuropathies was admitted for elective dilatation and curettage (D&C). Immediately after she complained of left-sided paraesthesia and later became disoriented, with incoherent speech, inability to obey commands, opsoclonus of the eyes and myoclonic jerks. Investigations including onconeuronal antibodies, cerebrospinal fluid analysis, and imaging were normal. She was treated with intravenous methylprednisolone with rapid improvement. Previous surgeries with anaesthesia were uncomplicated. The anaesthetic agents used for the D&C were fentanyl and propofol. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Anaesthesia; Neuroopthalmology

Mesh:

Substances:

Year:  2017        PMID: 28432174      PMCID: PMC5534871          DOI: 10.1136/bcr-2017-219859

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  1 in total

1.  Phencyclidine: A Rare Cause of Saccadic Intrusions.

Authors:  M N Shameer Nijam; Narmathey Thambirajah; Dhanushka Vithanawasam; Kumarangie Vithanage; Damith S Liyanage; I Kishara Gooneratne; Sunethra Senanayake
Journal:  Ann Indian Acad Neurol       Date:  2019-10-25       Impact factor: 1.383

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.